{
  "docId": "019de077-2202-715b-adea-57c1f9ae9ce5",
  "docSlug": "719db50244a96da2bbf79cc8f7d91684",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 26,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial structure with three cohorts (A, B, C) and a follow-up period, totaling 48 weeks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2202-715b-adea-57c1f9ae9ce5/18",
  "deckHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5",
  "deckJsonHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5.json",
  "deckAnchorHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.67,
        "x": 0.3,
        "y": 0.678
      },
      "kind": "callout",
      "text": "Primary objective: evaluate safety, tolerability and antiviral activity of imdusiran and NA therapy in combination with durvalumab. N=30 virologically-suppressed patients randomized into 3 separate cohorts",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f299a1a0-319b-4bd2-a0ad-d888bc76bd21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.54,
        "w": 0.634,
        "x": 0.335,
        "y": 0.177
      },
      "kind": "diagram",
      "text": "A, B, C cohorts followed by 48 weeks follow-up",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82ec1f13-2509-4f77-b464-25f0f90dd5c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.22,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Imdusiran in combination with NA therapy and intermittent low doses of durvalumab, an anti-PD-L1 monoclonal antibody. Screening initiated in 1H 2024",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fab8d57-a81e-4b04-abc6-5d43242b59b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.22,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "IM-PROVE III: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fbe64c5-8c31-4b79-9a00-a3ec7d0e8a54",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "cf8c5a5a-d436-4497-ae0d-437dcf62041e",
      "evidence": "The slide uses a horizontal timeline to represent the clinical trial phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}